On March 25, Shandong Sinobioway Biomedicine Co.Ltd(002581) replied to the letter of concern, saying that due to the particularity of ginseng asset inventory of Jilin Weiming Tianren traditional Chinese Medicine Technology Development Co., Ltd., a wholly-owned subsidiary of the company, and the risk factors that the company has been issued with qualified opinion audit reports for four consecutive years, no accounting firm has been invited to cooperate with the company on annual audit.
Shandong Sinobioway Biomedicine Co.Ltd(002581) introduced that the company has been actively promoting the selection and employment of accounting firms in 2021. The management of the company has invited more than 10 accounting firms and actively carried out preliminary investigation, business communication, negotiation and commercial due diligence with various accounting firms.
According to the official website of Shenzhen Stock Exchange, Shandong Sinobioway Biomedicine Co.Ltd(002581) made an appointment to disclose the annual report of 2021 on April 30. At present, it is only about one month away from its appointment time.
